DK0805807T3 - 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme - Google Patents

2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme

Info

Publication number
DK0805807T3
DK0805807T3 DK95940839T DK95940839T DK0805807T3 DK 0805807 T3 DK0805807 T3 DK 0805807T3 DK 95940839 T DK95940839 T DK 95940839T DK 95940839 T DK95940839 T DK 95940839T DK 0805807 T3 DK0805807 T3 DK 0805807T3
Authority
DK
Denmark
Prior art keywords
benzopyran
methoxyphenyl
oxo
amino
proliferative diseases
Prior art date
Application number
DK95940839T
Other languages
English (en)
Inventor
James Bridges Alexander
Robert Saltiel Alan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0805807T3 publication Critical patent/DK0805807T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
DK95940839T 1995-01-24 1995-11-27 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme DK0805807T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/378,131 US5525625A (en) 1995-01-24 1995-01-24 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
PCT/US1995/015373 WO1996022985A1 (en) 1995-01-24 1995-11-27 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-[1]benzopyran for treating proliferative disorders

Publications (1)

Publication Number Publication Date
DK0805807T3 true DK0805807T3 (da) 2000-01-17

Family

ID=23491857

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95940839T DK0805807T3 (da) 1995-01-24 1995-11-27 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-(1)-benzopyran til behandling af proliferative sygdomme

Country Status (12)

Country Link
US (1) US5525625A (da)
EP (1) EP0805807B1 (da)
JP (1) JPH10512878A (da)
AT (1) ATE181913T1 (da)
CA (1) CA2208075A1 (da)
DE (1) DE69510696T2 (da)
DK (1) DK0805807T3 (da)
ES (1) ES2137554T3 (da)
GR (1) GR3031295T3 (da)
NZ (1) NZ297320A (da)
WO (1) WO1996022985A1 (da)
ZA (1) ZA96528B (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
AU6472998A (en) 1997-03-28 1998-10-22 Research Foundation Of The State University Of New York, The Antisense oligonucleotides for mitogen-activated protein kinases as therapy for breast cancer
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
JP2002509536A (ja) * 1997-07-01 2002-03-26 ワーナー−ランバート・カンパニー ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用
AU757046B2 (en) * 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6319955B1 (en) 1998-01-06 2001-11-20 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
AU1951499A (en) * 1998-01-06 1999-07-26 General Hospital Corporation, The Use of mek1 inhibitors as protective agents against damage due to ischemia
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
WO1999048528A1 (en) * 1998-03-24 1999-09-30 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
AU1127700A (en) * 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
TR200101704T2 (tr) * 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
IL143236A0 (en) * 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
DE69924641D1 (de) * 1999-01-07 2005-05-12 Warner Lambert Company Llc Mor Behandlung von asthma anhand von mek-inhibitoren
GEP20032999B (en) * 1999-01-13 2003-06-25 Warner Lambert Co 1-Heterocycle Substituted Diarylamines
CA2349467A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
AU2201500A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
CA2348236A1 (en) * 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
WO2000050030A1 (en) * 1999-02-25 2000-08-31 Ted Ebendal New use
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
GB9920910D0 (en) * 1999-09-03 1999-11-10 Indena Spa Novel chalcones
US7001905B2 (en) * 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
EP1365796A2 (en) 2000-09-01 2003-12-03 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
EP1420778B1 (en) * 2001-03-06 2006-11-22 Dorian Bevec Use of mek inhibitors for treating virus induced hemorrhagic shock or fever
EP1409656A4 (en) * 2001-03-12 2005-01-12 Darley Pharmaceuticals Ltd SCREENING OF PHEROMONAL COMPOUNDS OF NON-STEROID AND NON-PEPTIDE INVERTEBRATE HAVING ACTIVITY MODULATING MITOGEN-ACTIVATED PROTEIN KINASE
US6806293B1 (en) * 2001-03-12 2004-10-19 Darley Pharmaceuticals Ltd Use of pheromone compounds having MAP kinase modulating activity
EP1377312A4 (en) * 2001-03-22 2004-10-06 Andel Inst Van ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS
IL149462A0 (en) * 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
KR20020096367A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 관절염 예방 또는 치료제 및 그것의 스크리닝 방법
KR20020096368A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 연골세포의 분화촉진, 연골세포의 탈분화 억제 또는탈분화된 연골세포의 재분화 촉진제, 그것의 스크리닝방법 및 그것을 이용한 연골세포의 제조방법
DOP2003000556A (es) * 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
BR0307060A (pt) * 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
CA2475206A1 (en) * 2002-02-15 2003-08-15 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
TWI343377B (en) * 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2003077855A2 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
ATE429250T1 (de) * 2003-02-26 2009-05-15 Kowa Co Mittel zur behandlung der allergischen kontaktdermatitis
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
BRPI0412851A (pt) * 2003-07-24 2006-10-03 Warner Lambert Co benzamidazóis de n-metila-substituìdos
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US20050130954A1 (en) * 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
AR051248A1 (es) * 2004-10-20 2007-01-03 Applied Research Systems Derivados de 3-arilamino piridina
JP2008520615A (ja) * 2004-11-24 2008-06-19 ラボラトワール セローノ ソシエテ アノニム 過増殖性障害を処置するためのｍｅｋ阻害剤としての新規４−アリールアミノピリドン誘導体
CN102898364A (zh) 2005-05-18 2013-01-30 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
WO2007021933A2 (en) * 2005-08-12 2007-02-22 The General Hospital Corporation Methods and compositions for use in treating vascular diseases and conditions
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006032A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN101511842B (zh) 2006-07-06 2012-10-31 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
SI2173723T1 (sl) * 2007-07-05 2011-12-30 Array Biopharma Inc Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze
US20090258939A1 (en) * 2007-07-31 2009-10-15 Wendye Robbins Pyrone analog compositions and methods
US20090062255A1 (en) * 2007-08-17 2009-03-05 Thallion Pharmaceuticals Inc. Tumor-targeting evaluation methodology and compounds related thereto
JP5346345B2 (ja) * 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
EP2240455B1 (en) * 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
SI2307376T1 (sl) * 2008-08-04 2016-02-29 Merck Patent Gmbh Nove spojine fenilamino izonikotinamida
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
ES2575995T3 (es) 2010-08-05 2016-07-04 Case Western Reserve University Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
KR20140022053A (ko) 2011-04-01 2014-02-21 제넨테크, 인크. Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
CA2836364C (en) 2011-05-25 2021-01-26 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN105229144A (zh) 2013-02-22 2016-01-06 细胞动力学国际有限公司 通过组合的遗传工程和化学工程经由正向编程产生肝细胞
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
WO2020051370A1 (en) * 2018-09-06 2020-03-12 North Carolina Central University Discovery of novel potent inhibitors of the map3k mekk2
WO2021043724A1 (en) 2019-09-02 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816466A (en) * 1971-12-22 1974-06-11 Warner Lambert Co Flavanoid ring systems
US5116954A (en) * 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
JPH05286962A (ja) * 1992-02-14 1993-11-02 Kyowa Hakko Kogyo Co Ltd ５−アミノフラボン誘導体

Also Published As

Publication number Publication date
DE69510696T2 (de) 1999-12-23
DE69510696D1 (de) 1999-08-12
ZA96528B (en) 1996-08-15
ATE181913T1 (de) 1999-07-15
AU4245696A (en) 1996-08-14
MX9704649A (es) 1997-09-30
NZ297320A (en) 1999-05-28
EP0805807B1 (en) 1999-07-07
ES2137554T3 (es) 1999-12-16
CA2208075A1 (en) 1996-08-01
AU690400B2 (en) 1998-04-23
EP0805807A1 (en) 1997-11-12
GR3031295T3 (en) 1999-12-31
JPH10512878A (ja) 1998-12-08
US5525625A (en) 1996-06-11
WO1996022985A1 (en) 1996-08-01

Similar Documents

Publication Publication Date Title
ES2137554T3 (es) 2-(2-amino-3-metoxifenil)-4-oxo-4h-(1)benzopirano para el tratamiento de desordenes proliferantes.
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
PL336788A1 (en) Probucol monoesters in treating circulatory system and inflammatory diseases
MY121548A (en) Compounds and methods for the treatment of cancer
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
DK0786991T3 (da) Polyaminforbindelsre til behandling af proliferative karsygdomme
ES2064119T3 (es) Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa.
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
NO962221L (no) Anvendelse av dimeticon for behandling av konstipasjon
DK0869813T3 (da) Anvendelse af beta-interferoner til behandling af restenose
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE59908268D1 (de) Khellin-zubereitung und deren verwendung zur topischen therapie
UA10928C2 (uk) Спосіб профілактики гіперхолестериhемії
NO984198L (no) FremgangsmÕte for behandling av aggresjon
SE9301606D0 (sv) Composition for the treatment of impaired hair growth
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE302605T1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
UA8280A (uk) Спосіб лікування псоріазу
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin